Clinical Trial Update: A Study of 177Lu-PSMA-617 in People With Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating 177Lu-PSMA-617 in patients with gliomas and related subtypes and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Astrocytoma Idh-wildtype
• Diffuse Hemispheric Glioma H3 G34-mutant
• Diffuse Midline Glioma H3 K27-altered
• Diffuse Pediatric-type High-grade Glioma H3-wildtype and Idh-wildtype
• Glioblastoma Idh-wildtype
• Glioma

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) | Phase 1 | Status: RECRUITING